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Do TZDs increase the risk of heart 
failure for patients with diabetes?
■ Evidence summary
A retrospective cohort study of health
insurance claims compared the incidence of
CHF among 5441 patients with diabetes
who had taken TZDs (rosiglitazone, trogli-
tazone, or pioglitazone) vs 28,103 who had
not. Patients were allowed other oral
agents and insulin, and they were followed
for up to 6 years. The TZD group had
more patients on insulin and with pre-exist-
ing comorbidities. Based on Kaplan-Meier
estimates, which control for censored infor-
mation, the incidence of new heart failure
at 40 months was 8.2% in the TZD group
and 5.3% in the non-TZD group (number
needed to harm [NNH]=34.5). Using a
multivariate analysis that controlled for the
coadministration of insulin, the hazard
ratio for TZD use was 1.76 (95% confi-
dence interval [CI], 1.43–2.17).1 The 
incidence of CHF was 3.24% in the trogli-
tazone group (n=1665), 2.39% in the
rosiglitazone group (n=1882), and 1.63%
in the pioglitazone group (n=1347). The
difference in these rates is not statistically
significant. Of the 28,103 patients not on a
TZD, 1.41% developed heart failure.
Individual agents were not compared 
with placebo.
A manufacturer-sponsored study that
combined data from 4 separate unpublished
randomized controlled trials compared the
incidence of CHF at 1 year for patients treat-
ed with pioglitazone (as monotherapy and in
combination with other oral agents) with
those treated only with other oral agents.
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C L I N I C A L C O M M E N T A R Y
Consider stopping TZDs 
for patients developing edema or CHF
Improved glycemic control decreases the risk of
end organ damage and heart failure in  patients
with diabetes. Thiazolidinediones are very useful
drugs, particularly for patients with marked insulin
resistance and hyperlipidemia. However, they do
precipitate edema and heart failure. The edema
can be severe enough to lead to discontinuation 
of the drug, and the risk of heart failure limits the
population in which they can be used. They can be
used safely in some cardiac patients but, as noted
in the article, they should be avoided or used with
caution in patients with CHF. Patients taking a TZD
who subsequently develop edema should be 
carefully evaluated for CHF.
Richard Hoffman, MD
Chesterfield Family Practice,
Richmond, Va
Patients with diabetes who take thiazolidinediones
(TZDs) have a higher incidence of congestive heart
failure (CHF) than those who do not; the incidence
of CHF is similar with the use of pioglitazone
(Actos), troglitazone (Rezulin), or rosiglitazone
(Avandia) (strength of recommendation [SOR]: B,
based on a large retrospective cohort study).
However, patients on regimens that include 
pioglitazone but not insulin have lower rates of
CHF than those taking insulin but not pioglitazone
(SOR: B, based on a retrospective cohort study).
Still, patients starting any TZD should be warned
of the possibility of CHF and should be monitored
for its development. TZDs are contraindicated for
patients with class III and IV CHF (SOR: C, based
on expert opinion).
E V I D E N C E - B A S E D A N S W E R
TZDs are useful
for patients with
marked insulin
resistance, but
they do precipitate
edema and heart
failure
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FAST TRACK
Cardiac failure was noted in 12 of 1857 in
the pioglitazone group vs 10 of 1856 sub-
jects in the non-pioglitazone groups (not sta-
tistically significant). The paper did not com-
ment on how the patients were recruited,
how outcomes were measured, or why the 4
original studies were not published.2
Another manufacturer-sponsored ret-
rospective cohort study of pioglitazone
analyzed insurance claims data to com-
pare the incidence of CHF among 1668
adult patients taking pioglitazone (and
possibly other medications, but not
insulin) vs 1668 adult patients taking
insulin (and possibly other medications,
but not a TZD). The 2 groups were
matched in terms of comorbid conditions,
but statistical analysis did not take disease
severity into account. The incidence of
CHF was 2% of pioglitazone users com-
pared with 4% of patients using insulin
(NNH for insulin=50). In addition, CHF-
related hospitalizations were 0.7% for
CHF in the pioglitazone group vs 2.5% in
the insulin group (NNH for insulin=55).
Both of these findings are statistically 
significant.3
Recommendations from others
The American Diabetes Association/
American Heart Association recommends
that patients be evaluated for heart disease
or heart failure before starting TZD thera-
py and monitored for symptoms thereafter.
Patients who are at risk for developing
CHF, who already have New York Heart
Association class I or II CHF, or who take
insulin should begin TZD therapy with
low doses that are titrated up gradually.
The US Food and Drug Administration
has not approved TZDs for patients with
class III or IV CHF, as there are no studies
in these populations.4
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What are 
Clinical Inquiries?
Clinical Inquiries answer recent questions from the
practices of family physicians.  Practicing family 
physicians choose the most relevant questions 
submitted through a web-based voting system 
operated by the Family Physicians Inquiries Network
(FPIN; online at www.fpin.org). 
FPIN is national, not-for-profit consortium of 
family medicine departments, community residency
programs, academic health sciences libraries, primary
care practice-based research networks, and other 
specialists. Once questions are selected, FPIN editors
then organize teams of clinicians and librarians to
answer them based on systematic review of the world
literature. Answers are developed through an explicit,
systematic method:
❚ FPIN librarians and editors identify questions recently
answered in best evidence sources (e.g. Cochrane
Reviews, Clinical Evidence, the US Preventive
Services Task Force, Evidence Based Guidelines, 
a published systematic review).
❚ FPIN librarians then conduct systematic and 
standardized literature searches of best evidence
sources, Medline, and other databases in collabora-
tion with an FPIN clinician or clinicians. If a best 
evidence source has been identified, the search
begins from the date of the search conducted for that
source. Otherwise, the searches are comprehensive. 
❚ FPIN clinician authors then choose the highest 
quality original research sources, and critically
appraise the research and integrate the findings 
in the Evidence Based Answer and Evidence
Summary section of Clinical Inquiries. Authoritative
sources are also quoted in the “Recommendations
from Others” section of the Clinical Inquiry.
❚ Each Clinical Inquiry is reviewed by 4 or more peers
or editors before publication in JFP.
❚ FPIN medical librarians are accountable for the 
thoroughness of the literature search, for recording
the databases searched, search hedges used and
the search terms.  The details of each search is
available to any interested reader 
(contact managingeditor@fpin.org).
❚ Finally, a practicing family physician or other 
clinician writes an accompanying commentary 
to provide a clinical perspective.
